# Phase2a Primaquine Dose Escalation Study

> **NCT01743820** · PHASE2 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 81 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** dihydroartemisinin-piperaquine
- **DRUG:** 0.125 mg/kg Primaquine
- **DRUG:** 0.5 mg/kg Primaquine
- **DRUG:** 0.25 mg/kg Primaquine
- **DRUG:** 0.0625 mg/kg Primaquine

## Key facts

- **NCT ID:** NCT01743820
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2015-01-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01743820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01743820, "Phase2a Primaquine Dose Escalation Study". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01743820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*